SNS-314 MESYLATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H15ClN6OS2.CH4O3S
Molecular Weight	527.04
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.ClC1=CC=CC(NC(=O)NC2=NC=C(CCNC3=C4SC=CC4=NC=N3)S2)=C1

InChI

InChIKey=FYCODPVDEFFWSR-UHFFFAOYSA-N

InChI=1S/C18H15ClN6OS2.CH4O3S/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16;1-5(2,3)4/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C18H15ClN6OS2
Molecular Weight	430.934
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800019470 | https://www.sunesis.com/data-pdf/314/SNS-314_Poster.pdf | https://www.drugbank.ca/drugs/DB06134 | https://www.ncbi.nlm.nih.gov/pubmed/19372566

SNS 314 is a selective small molecule inhibitor of Aurora kinases A, B and C. The compound was being developed by Sunesis Pharmaceuticals for the treatment of cancer. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and it was being tested in single agent Phase 1 studies in patients with advanced solid tumours.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Aurora kinase A 4 Target ID: O14965 Gene ID: 6790.0 Gene Symbol: AURKA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8504	9.0 nM [IC50]
Aurora kinase B 3 Target ID: Q96GD4\|\|\|O60446 Gene ID: 9212.0 Gene Symbol: AURKB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8504	31.0 nM [IC50]
Aurora kinase C 2 Target ID: Q9UQB9 Gene ID: 6795.0 Gene Symbol: AURKC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8504	3.4 nM [IC50]
High affinity nerve growth factor receptor 3 Target ID: P04629\|\|\|Q7Z5C3 Gene ID: 4914.0 Gene Symbol: NTRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8504	12.0 nM [IC50]
BDNF/NT-3 growth factors receptor 4 Target ID: Q16620 Gene ID: 4915.0 Gene Symbol: NTRK2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8504	5.0 nM [IC50]

AUC

Value	Dose	Co-administered	Analyte	Population
2090 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19186057/	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SNS-314 plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3650 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19186057/	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		SNS-314 plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19646866/	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SNS-314 plasma	Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

PubMed

Title	Date	PubMed
Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.	2017-04-25	28427193
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.	2010-03	19649632
Discovery of a potent and selective aurora kinase inhibitor.	2008-09-01	18678489

Patents

Sample Use Guides

In Vivo Use Guide

Mice: In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 led to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h, indicating effective Aurora-B inhibition in vivo.

Route of Administration: Intraperitoneal

In Vitro Use Guide

SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively and less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:45 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:45 GMT 2025`
Record UNII	KGW32FDY3U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SNS-314 MESYLATE

Common Name

English

UREA, N-(3-CHLOROPHENYL)-N'-(5-(2-(THIENO(3,2-D)PYRIMIDIN-4-YLAMINO)ETHYL)-2-THIAZOLYL)-, METHANESULFONATE (1:1)

Preferred Name

English

Code System Code Type Description

EPA CompTox

DTXSID10648376